SCHEMBL30712098

SCHEMBL30712098

NC(=O)C(=O)c1c[nH]c2ccc(F)c(O)c12

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HTR1D P28221 3/20 0.39
▸ HTR1B P28222 3/20 0.39
▸ F7 P08709 1/20 0.38
▸ F3 P13726 1/20 0.38
▸ HTR2A P28223 1/20 0.37
▸ GPR84 Q9NQS5 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ MPO P05164 3/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ HTR1A P08908 1/20 0.34
▸ HTR7 P34969 1/20 0.34
▸ NR4A2 P43354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31708151 0.82 IGF1R (0.38) GPR84NR4A2
SCHEMBL10078403 0.79 HTR2A (0.49) HTR2AGPR84ALDH1A1ATMGAA
SCHEMBL31708084 0.79 — —
SCHEMBL30712086 0.79 GABRP (0.43) —
SCHEMBL31708196 0.77 NPC1 (0.43) —
SCHEMBL21366320 0.71 KDM4E (0.59) F7F3HTR2AGPR84ALDH1A1
SCHEMBL25241237 0.71 GPR84 (0.47) F7F3HTR2AGPR84KDM4E
SCHEMBL2535534 0.71 F7 (0.71) F7F3NR4A2
SCHEMBL31708197 0.70 HTR2A (0.63) HTR1DHTR1BHTR2AGPR84MPO
SCHEMBL12596191 0.70 GPR84 (0.50) HTR1DHTR1BHTR2AGPR84MPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4635492-A2 TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS Gilgamesh Pharmaceuticals, Inc. (US) 2025-10-22 — — EP disclosed
EP-4551212-A2 TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS Gilgamesh Pharmaceuticals, Inc. (US) 2025-05-14 — — EP disclosed
WO-2024035757-A2 TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2024-02-15 — — WO disclosed
Send feedback